PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page
FDA Approves New Treatment for HSDD in Premenopausal Women

FDA Approves New Treatment for HSDD in Premenopausal Women

by PEPID Newsroom | Jun 21, 2019 | Alerts

FDA approves bremelanotide  (Vyleesi, AMAG Pharmaceuticals) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Bremelanotide is the first-in-class melanocortin 4 receptor agonist for HSDD, and joins Flibanserin as...

Recent Posts

  • Sleep Awareness Week: Why Sleep Health Should Be Part of Every Wellness Visit
  • Heart Health Month in Practice: What Clinicians Should Watch for in February
  • National Blood Donor Month: How Clinicians Can Encourage Lifesaving Donations
  • Holiday Health Hazards: Common ER Visits and How to Prevent Them
  • What Is a DNP? Everything You Need to Know About the Doctor of Nursing Practice

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved